All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

ipratropium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
atropine derivatives	1475	60205-81-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ipratropium ipratropium bromide ipratropium bromide hydrate ipratropium bromide monohydrate	A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic. Molecular weight: 332.46 Formula: C20H30NO3 CLOGP: -2.19 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 46.53 ALOGS: -5.48 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
0.24	mg	N
0.12	mg	Inhal.aerosol
0.12	mg	Inhal.powder
0.30	mg	Inhal.solution

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.01 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	3 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	5.10 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	31.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.95 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.64 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 29, 1986	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	1159.58	10.79	839	48159	88498	50467628
Wheezing	697.25	10.79	535	48463	61512	50494614
Obstructive airways disorder	455.30	10.79	246	48752	15406	50540720
Dyspnoea	416.03	10.79	1315	47683	546293	50009833
Chronic obstructive pulmonary disease	410.68	10.79	370	48628	53065	50503061
Sleep disorder due to a general medical condition	292.98	10.79	143	48855	7228	50548898
Productive cough	209.98	10.79	257	48741	52437	50503689
Full blood count abnormal	209.84	10.79	177	48821	23211	50532915
Pneumonia	205.06	10.79	815	48183	377586	50178540
Cough	194.35	10.79	593	48405	240671	50315455
Chest discomfort	165.68	10.79	311	48687	92411	50463715
Drug intolerance	125.78	10.79	29	48969	219075	50337051
Therapeutic product effect incomplete	114.24	10.79	265	48733	91250	50464876
Drug ineffective	114.21	10.79	410	48588	818923	49737203
Nasal congestion	113.93	10.79	189	48809	50931	50505195
Completed suicide	113.61	10.79	3	48995	131886	50424240
Contraindicated product administered	110.45	10.79	9	48989	148949	50407177
Respiratory failure	109.42	10.79	260	48738	90921	50465205
Alopecia	108.22	10.79	51	48947	244996	50311130
Breath sounds abnormal	104.84	10.79	75	48923	7717	50548409
Synovitis	99.18	10.79	5	48993	123860	50432266
Pemphigus	99.00	10.79	4	48994	120162	50435964
Rheumatoid arthritis	97.67	10.79	37	48961	202513	50353613
Systemic lupus erythematosus	97.64	10.79	11	48987	140611	50415515
Sputum discoloured	91.61	10.79	87	48911	13308	50542818
Dyspnoea exertional	87.91	10.79	169	48829	51064	50505062
Loss of personal independence in daily activities	83.20	10.79	199	48799	69851	50486275
Glossodynia	82.90	10.79	8	48990	115561	50440565
Treatment failure	81.40	10.79	17	48981	137620	50418506
Arthropathy	80.99	10.79	26	48972	157880	50398246
Nasal turbinate hypertrophy	78.08	10.79	28	48970	642	50555484
Bronchial neoplasm	77.63	10.79	25	48973	408	50555718
Ventricular failure	73.21	10.79	23	48975	345	50555781
Bronchial haemorrhage	73.14	10.79	25	48973	495	50555631
Hypercapnia	72.72	10.79	49	48949	4578	50551548
Sleep apnoea syndrome	72.61	10.79	102	48896	23766	50532360
Hyper IgE syndrome	69.48	10.79	23	48975	411	50555715
Rhonchi	69.11	10.79	37	48961	2270	50553856
Toxicity to various agents	68.40	10.79	63	48935	212436	50343690
Upper-airway cough syndrome	65.17	10.79	59	48939	8491	50547635
Bronchospasm	64.94	10.79	76	48922	14778	50541348
Wound	64.79	10.79	12	48986	105782	50450344
Acute respiratory failure	63.54	10.79	106	48892	28676	50527450
Maternal exposure during pregnancy	63.49	10.79	38	48960	159740	50396386
Hepatic enzyme increased	63.08	10.79	27	48971	137353	50418773
Blood test abnormal	61.70	10.79	65	48933	11254	50544872
Respiration abnormal	61.60	10.79	46	48952	5056	50551070
Endometrial ablation	60.80	10.79	25	48973	838	50555288
Joint swelling	60.39	10.79	90	48908	245196	50310930
Infusion related reaction	58.53	10.79	47	48951	169510	50386616
Forced expiratory volume decreased	58.44	10.79	42	48956	4352	50551774
Middle insomnia	57.73	10.79	59	48939	9862	50546264
Off label use	57.72	10.79	250	48748	474176	50081950
Bronchitis	57.37	10.79	226	48772	103933	50452193
Rhinitis	55.03	10.79	53	48945	8248	50547878
Pericarditis	54.99	10.79	6	48992	78683	50477443
Prolonged expiration	54.61	10.79	22	48976	699	50555427
Abdominal discomfort	54.14	10.79	88	48910	231553	50324573
Bronchial disorder	54.07	10.79	25	48973	1117	50555009
Rales	53.86	10.79	57	48941	9921	50546205
Arthralgia	53.45	10.79	231	48767	438471	50117655
Restrictive pulmonary disease	51.74	10.79	26	48972	1398	50554728
Pain	51.55	10.79	339	48659	578564	49977562
Hypoxia	51.03	10.79	136	48862	50987	50505139
Therapeutic product effect decreased	50.44	10.79	35	48963	136015	50420111
Rash	48.73	10.79	238	48760	437233	50118893
Cardiac murmur	48.52	10.79	56	48942	10728	50545398
Asthma-chronic obstructive pulmonary disease overlap syndrome	48.47	10.79	18	48980	457	50555669
Oxygen saturation decreased	47.90	10.79	168	48830	73080	50483046
Heart sounds	46.95	10.79	19	48979	611	50555515
PO2 decreased	46.64	10.79	24	48974	1357	50554769
Eosinophilia	45.66	10.79	72	48926	18580	50537546
Discomfort	45.60	10.79	24	48974	108356	50447770
Haemoptysis	44.64	10.79	85	48913	25488	50530638
Blood immunoglobulin E increased	44.47	10.79	28	48970	2331	50553795
Bronchiectasis	43.93	10.79	52	48946	10231	50545895
Throat clearing	43.90	10.79	22	48976	1176	50554950
Exposure during pregnancy	43.71	10.79	32	48966	120983	50435143
Sight disability	43.57	10.79	12	48986	110	50556016
Swelling	43.56	10.79	80	48918	200792	50355334
Lower respiratory tract infection	43.40	10.79	195	48803	95006	50461120
Drug abuse	43.28	10.79	4	48994	59842	50496284
Anti-cyclic citrullinated peptide antibody positive	43.22	10.79	8	48990	70579	50485547
PCO2 increased	41.92	10.79	21	48977	1122	50555004
Myocardial infarction	41.82	10.79	184	48814	88843	50467283
Tachypnoea	40.97	10.79	60	48938	14517	50541609
Oesophageal spasm	40.17	10.79	26	48972	2270	50553856
Sinus tachycardia	39.79	10.79	73	48925	21281	50534845
Gastrooesophageal reflux disease	39.01	10.79	162	48836	76266	50479860
Venous pressure jugular increased	39.01	10.79	16	48982	533	50555593
Thermohypoaesthesia	38.90	10.79	11	48987	112	50556014
Influenza B virus test positive	37.95	10.79	13	48985	259	50555867
Vocal cord dysfunction	37.90	10.79	14	48984	350	50555776
Total lung capacity increased	37.84	10.79	17	48981	710	50555416
Upper respiratory tract infection	37.08	10.79	144	48854	65754	50490372
Lung hyperinflation	36.52	10.79	19	48979	1099	50555027
Status asthmaticus	35.63	10.79	17	48981	816	50555310
Cardiac failure congestive	35.61	10.79	169	48829	84213	50471913
Pulmonary hypertension	35.49	10.79	91	48907	33326	50522800
Breast conserving surgery	35.23	10.79	17	48981	837	50555289
Rib deformity	35.20	10.79	11	48987	162	50555964
Respiratory rate increased	35.14	10.79	49	48949	11336	50544790
Respiratory disorder	34.24	10.79	86	48912	31101	50525025
Infective pulmonary exacerbation of cystic fibrosis	33.80	10.79	40	48958	7869	50548257
Oesophageal pain	33.24	10.79	25	48973	2777	50553349
Tracheomalacia	33.22	10.79	10	48988	129	50555997
Airway peak pressure increased	33.14	10.79	12	48986	283	50555843
Nasal polyps	33.02	10.79	24	48974	2530	50553596
Sinus disorder	33.01	10.79	62	48936	18396	50537730
Multimorbidity	32.83	10.79	14	48984	515	50555611
Dysphonia	32.47	10.79	97	48901	38795	50517331
Helicobacter infection	31.82	10.79	5	48993	49697	50506429
Polycystic ovaries	31.34	10.79	23	48975	2461	50553665
Respiratory distress	31.32	10.79	82	48916	30407	50525719
Total lung capacity decreased	31.26	10.79	18	48980	1273	50554853
Infective exacerbation of chronic obstructive airways disease	31.05	10.79	17	48981	1091	50555035
Blood insulin abnormal	30.97	10.79	7	48991	25	50556101
FEV1/FVC ratio decreased	30.82	10.79	8	48990	57	50556069
Granuloma	30.30	10.79	30	48968	4828	50551298
Rhinitis allergic	30.08	10.79	36	48962	7164	50548962
Bronchopulmonary aspergillosis allergic	29.90	10.79	17	48981	1174	50554952
Nasal obstruction	29.32	10.79	16	48982	1020	50555106
Heart rate increased	29.23	10.79	150	48848	77100	50479026
Bundle branch block left	29.12	10.79	33	48965	6197	50549929
Lung disorder	28.63	10.79	102	48896	44697	50511429
Cyanosis	28.41	10.79	52	48946	15132	50540994
Type 2 diabetes mellitus	28.01	10.79	85	48913	34290	50521836
Atrial fibrillation	27.69	10.79	181	48817	101564	50454562
Drug hypersensitivity	27.62	10.79	137	48861	250873	50305253
Asthmatic crisis	27.41	10.79	18	48980	1610	50554516
Respiratory acidosis	26.61	10.79	31	48967	5997	50550129
Lactose intolerance	26.28	10.79	21	48977	2549	50553577
Kyphosis	26.17	10.79	20	48978	2275	50553851
Separation anxiety disorder	26.01	10.79	6	48992	24	50556102
Blister	25.51	10.79	27	48971	85391	50470735
Affective disorder	25.17	10.79	28	48970	5153	50550973
Diarrhoea	25.12	10.79	410	48588	588066	49968060
Dyslipidaemia	25.12	10.79	30	48968	5958	50550168
Abortion spontaneous	25.01	10.79	5	48993	41767	50514359
Blood pH decreased	24.98	10.79	20	48978	2435	50553691
Intentional overdose	24.62	10.79	15	48983	62489	50493637
Respiratory gas exchange disorder	24.30	10.79	10	48988	336	50555790
Reversible airways obstruction	24.11	10.79	14	48984	1006	50555120
Product use issue	23.94	10.79	70	48928	149405	50406721
Irritable bowel syndrome	23.77	10.79	10	48988	51431	50504695
Psoriatic arthropathy	23.64	10.79	8	48990	47024	50509102
Pneumonia viral	23.50	10.79	31	48967	6803	50549323
Injection site pain	23.35	10.79	45	48953	110979	50445147
Blood bicarbonate decreased	23.15	10.79	20	48978	2705	50553421
Pulmonary function test decreased	23.15	10.79	22	48976	3366	50552760
Amaurosis	23.03	10.79	11	48987	529	50555597
Acute generalised exanthematous pustulosis	22.57	10.79	35	48963	8903	50547223
Respiratory tract infection	22.28	10.79	75	48923	31942	50524184
Intentional product use issue	22.21	10.79	25	48973	76893	50479233
Laryngeal stenosis	21.70	10.79	12	48986	785	50555341
Rectal prolapse	21.63	10.79	16	48982	1733	50554393
Optic ischaemic neuropathy	21.53	10.79	13	48985	1004	50555122
Rhinorrhoea	21.53	10.79	103	48895	51480	50504646
Brain hypoxia	21.44	10.79	10	48988	456	50555670
Oesophageal motility disorder	21.39	10.79	9	48989	320	50555806
Liver disorder	21.17	10.79	5	48993	37217	50518909
Chest pain	21.16	10.79	263	48735	176619	50379507
Coronary artery disease	21.01	10.79	70	48928	29656	50526470
Injection site bruising	20.80	10.79	5	48993	36763	50519363
Emphysema	20.75	10.79	34	48964	9059	50547067
Sleep disorder due to general medical condition, insomnia type	20.50	10.79	3	48995	31444	50524682
Depressive symptom	20.40	10.79	20	48978	3180	50552946
Aspiration	20.28	10.79	34	48964	9230	50546896
Blood lactic acid increased	20.24	10.79	26	48972	5559	50550567
Crystal arthropathy	20.20	10.79	8	48990	243	50555883
Frustration tolerance decreased	19.91	10.79	26	48972	5648	50550478
Peak expiratory flow rate abnormal	19.89	10.79	6	48992	78	50556048
Injection site reaction	19.71	10.79	12	48986	50020	50506106
Fatigue	19.57	10.79	529	48469	707072	49849054
Febrile neutropenia	19.33	10.79	41	48957	97626	50458500
Oropharyngeal discomfort	19.00	10.79	21	48977	3837	50552289
Unresponsive to stimuli	18.96	10.79	69	48929	30540	50525586
Humidity intolerance	18.79	10.79	8	48990	293	50555833
Impaired healing	18.75	10.79	24	48974	69762	50486364
Hypoventilation	18.72	10.79	21	48977	3900	50552226
Eye pruritus	18.67	10.79	39	48959	12495	50543631
Neuromyelitis optica spectrum disorder	18.64	10.79	11	48987	815	50555311
Eosinophil count abnormal	18.52	10.79	9	48989	450	50555676
Pupillary reflex impaired	18.45	10.79	15	48983	1866	50554260
Haematoma	18.25	10.79	68	48930	30442	50525684
Knee arthroplasty	18.19	10.79	6	48992	35840	50520286
Dystrophic calcification	17.88	10.79	6	48992	112	50556014
Sneezing	17.86	10.79	41	48957	14003	50542123
Hip arthroplasty	17.48	10.79	4	48994	30425	50525701
Influenza	17.35	10.79	147	48851	89391	50466735
Pulmonary oedema	17.12	10.79	93	48905	48845	50507281
Nausea	17.07	10.79	537	48461	704861	49851265
Injection site erythema	16.98	10.79	29	48969	74907	50481219
Nephrocalcinosis	16.97	10.79	11	48987	963	50555163
Appetite disorder	16.94	10.79	25	48973	6089	50550037
Heparin-induced thrombocytopenia	16.85	10.79	20	48978	3945	50552181
Lymphoedema	16.76	10.79	31	48967	9091	50547035
Red blood cell sedimentation rate increased	16.64	10.79	4	48994	29412	50526714
Upper airway obstruction	16.63	10.79	9	48989	564	50555562
Infusion site erythema	16.47	10.79	30	48968	8697	50547429
Malaise	16.40	10.79	433	48565	335099	50221027
Gastrointestinal disorder	16.03	10.79	43	48955	94413	50461713
Pneumonia staphylococcal	15.96	10.79	16	48982	2613	50553513
Staphylococcus test positive	15.85	10.79	18	48980	3388	50552738
Lung opacity	15.80	10.79	14	48984	1959	50554167
Lactic acidosis	15.69	10.79	69	48929	33286	50522840
Pneumonia respiratory syncytial viral	15.57	10.79	9	48989	641	50555485
C-reactive protein abnormal	15.30	10.79	4	48994	27805	50528321
Extensor plantar response	15.28	10.79	11	48987	1143	50554983
Glycosylated haemoglobin decreased	15.20	10.79	8	48990	474	50555652
Acute myocardial infarction	14.89	10.79	62	48936	29211	50526915
Respiratory alkalosis	14.69	10.79	15	48983	2504	50553622
Sputum purulent	14.66	10.79	10	48988	953	50555173
Pneumonia haemophilus	14.54	10.79	8	48990	518	50555608
Vascular parkinsonism	14.31	10.79	5	48993	106	50556020
Facial discomfort	14.30	10.79	4	48994	39	50556087
Hepatic function abnormal	14.09	10.79	7	48991	32674	50523452
Oedema peripheral	14.09	10.79	223	48775	157738	50398388
Chest X-ray abnormal	13.94	10.79	18	48980	3867	50552259
Skin lesion	13.90	10.79	57	48941	26670	50529456
Sinusitis	13.81	10.79	237	48761	170321	50385805
Hypertrophic cardiomyopathy	13.78	10.79	11	48987	1334	50554792
Idiopathic intracranial hypertension	13.72	10.79	14	48984	2335	50553791
Peak expiratory flow rate decreased	13.71	10.79	8	48990	580	50555546
Presyncope	13.70	10.79	53	48945	24145	50531981
Stress cardiomyopathy	13.49	10.79	26	48972	7861	50548265
Hyperlactacidaemia	13.31	10.79	14	48984	2419	50553707
Lung neoplasm malignant	13.28	10.79	39	48959	15445	50540681
Sarcoidosis	13.16	10.79	20	48978	4997	50551129
Stomatitis	13.13	10.79	52	48946	101292	50454834
Peripheral swelling	12.99	10.79	132	48866	205804	50350322
Pancytopenia	12.98	10.79	40	48958	83990	50472136
Pharyngeal mass	12.98	10.79	6	48992	268	50555858
Forced expiratory volume increased	12.81	10.79	3	48995	13	50556113
Psoriasis	12.80	10.79	30	48968	68970	50487156
Tachycardia	12.64	10.79	150	48848	99613	50456513
Inspiratory capacity decreased	12.49	10.79	4	48994	64	50556062
Respiratory tract congestion	12.41	10.79	36	48962	14163	50541963
Forced expiratory volume abnormal	12.16	10.79	4	48994	70	50556056
Laryngospasm	12.16	10.79	14	48984	2674	50553452
Vocal cord disorder	12.07	10.79	10	48988	1278	50554848
Cardiac disorder	12.01	10.79	77	48921	42902	50513224
Visceral pain	12.00	10.79	3	48995	18	50556108
Blood albumin decreased	11.99	10.79	34	48964	13202	50542924
Infusion site extravasation	11.94	10.79	23	48975	6953	50549173
Drug eruption	11.89	10.79	4	48994	23602	50532524
False positive investigation result	11.87	10.79	7	48991	518	50555608
Bone marrow failure	11.78	10.79	6	48992	27618	50528508
Pneumonia pseudomonal	11.71	10.79	12	48986	2011	50554115
Angle closure glaucoma	11.66	10.79	12	48986	2022	50554104
Chondrocalcinosis pyrophosphate	11.63	10.79	9	48989	1043	50555083
Foetal exposure during pregnancy	11.58	10.79	6	48992	27353	50528773
Blood glucose abnormal	11.42	10.79	22	48976	6650	50549476
Dysaesthesia	11.41	10.79	16	48982	3719	50552407
Abscess	11.35	10.79	35	48963	14237	50541889
Shock haemorrhagic	11.32	10.79	25	48973	8319	50547807
Multiple sclerosis relapse	11.31	10.79	15	48983	42949	50513177
Catarrh	11.25	10.79	6	48992	365	50555761
Cardiac asthma	11.18	10.79	4	48994	91	50556035
Tumour hyperprogression	11.14	10.79	4	48994	92	50556034
Tongue exfoliation	10.98	10.79	4	48994	96	50556030
Musculoskeletal stiffness	10.97	10.79	76	48922	128405	50427721
Barrett's oesophagus	10.92	10.79	7	48991	601	50555525
Generalised tonic-clonic seizure	10.80	10.79	6	48992	26304	50529822

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	618.73	11.23	430	35852	33419	29504826
Wheezing	429.48	11.23	343	35939	32897	29505348
Chronic obstructive pulmonary disease	378.91	11.23	349	35933	40606	29497639
Obstructive airways disorder	305.15	11.23	182	36100	10834	29527411
Dyspnoea	300.75	11.23	979	35303	325753	29212492
Asthma-chronic obstructive pulmonary disease overlap syndrome	192.18	11.23	60	36222	683	29537562
Full blood count abnormal	170.77	11.23	144	36138	14869	29523376
Sputum discoloured	155.08	11.23	98	36184	6465	29531780
Cough	147.88	11.23	414	35868	126313	29411932
Appendicolith	132.93	11.23	71	36211	3409	29534836
Nasal obstruction	127.87	11.23	41	36241	512	29537733
Pulmonary function test decreased	126.34	11.23	73	36209	4090	29534155
Sinus pain	120.50	11.23	40	36242	561	29537684
Pneumonia	111.21	11.23	721	35561	319451	29218794
Bronchiectasis	109.29	11.23	79	36203	6506	29531739
Chest discomfort	101.06	11.23	193	36089	45790	29492455
Productive cough	98.63	11.23	154	36128	31105	29507140
Stress	94.48	11.23	124	36158	21366	29516879
Forced expiratory volume decreased	89.83	11.23	51	36231	2762	29535483
Appendicitis	85.29	11.23	77	36205	8702	29529543
Mycobacterium avium complex infection	80.27	11.23	44	36238	2225	29536020
Emphysema	74.47	11.23	71	36211	8600	29529645
Cardiogenic shock	72.65	11.23	103	36179	19087	29519158
Completed suicide	72.18	11.23	12	36270	90234	29448011
Toxicity to various agents	71.19	11.23	65	36217	173596	29364649
Oxygen saturation decreased	69.00	11.23	163	36119	44774	29493471
Middle insomnia	67.46	11.23	56	36226	5652	29532593
Therapeutic product effect incomplete	67.46	11.23	149	36133	39156	29499089
Respiratory distress	65.93	11.23	131	36151	31975	29506270
Bronchitis	65.82	11.23	142	36140	36726	29501519
Nasal congestion	65.16	11.23	97	36185	18782	29519463
Toxic epidermal necrolysis	65.15	11.23	95	36187	18058	29520187
Lung consolidation	64.92	11.23	52	36230	4991	29533254
Drug abuse	63.05	11.23	11	36271	79872	29458373
Respiratory disorder	59.68	11.23	88	36194	16895	29521350
Lower respiratory tract infection	59.13	11.23	112	36170	26390	29511855
Osteopenia	58.00	11.23	45	36237	4123	29534122
Respiratory failure	56.90	11.23	253	36029	96878	29441367
Eosinophilia	56.20	11.23	99	36183	22062	29516183
Painful respiration	50.67	11.23	26	36256	1148	29537097
Sleep disorder due to a general medical condition	48.26	11.23	36	36246	3110	29535135
Throat irritation	47.09	11.23	56	36226	8729	29529516
Dyspnoea exertional	43.17	11.23	120	36162	36370	29501875
Tachypnoea	41.57	11.23	70	36212	15045	29523200
Fractional exhaled nitric oxide increased	41.21	11.23	16	36266	360	29537885
Chest injury	40.50	11.23	24	36258	1409	29536836
Bronchospasm	39.99	11.23	54	36228	9555	29528690
Walking aid user	37.26	11.23	23	36259	1454	29536791
Pleural thickening	36.82	11.23	14	36268	297	29537948
Pulmonary mass	33.94	11.23	53	36229	10695	29527550
Pulmonary function test abnormal	32.33	11.23	24	36258	2058	29536187
Genital herpes simplex	31.62	11.23	10	36272	119	29538126
General physical health deterioration	30.87	11.23	224	36058	102633	29435612
Hypoventilation	29.74	11.23	26	36256	2815	29535430
Hyperkaliuria	29.43	11.23	9	36273	95	29538150
Ventricular fibrillation	29.41	11.23	62	36220	15771	29522474
Hypercapnia	29.16	11.23	29	36253	3697	29534548
Foetal exposure during pregnancy	28.21	11.23	4	36278	33863	29504382
Secretion discharge	27.95	11.23	30	36252	4180	29534065
Febrile neutropenia	27.94	11.23	60	36222	112180	29426065
Total lung capacity abnormal	27.12	11.23	9	36273	126	29538119
Diarrhoea	26.85	11.23	270	36012	332428	29205817
Sensitivity to weather change	25.79	11.23	18	36264	1401	29536844
Abdominal distension	24.91	11.23	117	36165	45794	29492451
Oral candidiasis	24.76	11.23	46	36236	10676	29527569
Multiple organ dysfunction syndrome	24.73	11.23	147	36135	62969	29475276
COVID-19 treatment	24.59	11.23	10	36272	255	29537990
Overdose	24.00	11.23	38	36244	79781	29458464
Eye disorder	23.86	11.23	38	36244	7796	29530449
Wolff-Parkinson-White syndrome	23.45	11.23	9	36273	196	29538049
Upper-airway cough syndrome	22.81	11.23	23	36259	2980	29535265
Bronchitis viral	22.75	11.23	9	36273	213	29538032
Product prescribing error	22.13	11.23	60	36222	17916	29520329
Feeling cold	21.94	11.23	40	36242	9151	29529094
Blood immunoglobulin E decreased	21.80	11.23	6	36276	42	29538203
Dust allergy	21.60	11.23	11	36271	478	29537767
Aortic aneurysm	21.51	11.23	32	36250	6188	29532057
Infective pulmonary exacerbation of cystic fibrosis	21.45	11.23	32	36250	6204	29532041
Lung hyperinflation	21.39	11.23	13	36269	799	29537446
Forced vital capacity decreased	21.15	11.23	12	36270	649	29537596
Off label use	21.09	11.23	252	36030	300548	29237697
Lung disorder	20.78	11.23	83	36199	30279	29507966
Tachycardia foetal	20.71	11.23	9	36273	272	29537973
Bronchial wall thickening	20.67	11.23	14	36268	1038	29537207
Chronic respiratory failure	20.62	11.23	15	36267	1247	29536998
Plantar fasciitis	20.41	11.23	15	36267	1266	29536979
White blood cell count decreased	20.37	11.23	45	36237	83317	29454928
Myoglobin blood increased	20.37	11.23	18	36264	1977	29536268
Ascites	20.36	11.23	94	36188	36525	29501720
Pneumonitis	20.28	11.23	78	36204	27966	29510279
Treatment failure	20.22	11.23	10	36272	36929	29501316
Genital herpes	20.18	11.23	11	36271	550	29537695
Respiratory tract congestion	19.60	11.23	28	36254	5221	29533024
Brain natriuretic peptide increased	19.50	11.23	25	36257	4205	29534040
Bronchial hyperreactivity	19.17	11.23	15	36267	1391	29536854
Respiratory acidosis	19.05	11.23	25	36257	4303	29533942
Medication error	18.75	11.23	63	36219	21148	29517097
Sensation of foreign body	17.97	11.23	16	36266	1774	29536471
Hyponatraemia	17.86	11.23	143	36139	67490	29470755
Pneumothorax	17.65	11.23	51	36231	15791	29522454
Intentional overdose	17.50	11.23	13	36269	38515	29499730
Aggression	17.47	11.23	11	36271	35530	29502715
Bilirubin conjugated abnormal	17.35	11.23	6	36276	96	29538149
Acute respiratory failure	17.13	11.23	71	36211	26331	29511914
Carbon dioxide increased	16.88	11.23	12	36270	962	29537283
Blood immunoglobulin E increased	16.82	11.23	16	36266	1931	29536314
Neuropathy peripheral	16.82	11.23	39	36243	70988	29467257
Hypohidrosis	16.74	11.23	7	36275	192	29538053
Respiratory tract infection	16.12	11.23	49	36233	15602	29522643
Peak expiratory flow rate decreased	16.11	11.23	6	36276	120	29538125
Influenza	16.05	11.23	97	36185	41784	29496461
Bronchospasm paradoxical	16.01	11.23	5	36277	57	29538188
Rales	15.83	11.23	31	36251	7479	29530766
Type IIa hyperlipidaemia	15.71	11.23	6	36276	129	29538116
Hypoxia	15.25	11.23	105	36177	47274	29490971
Rhinalgia	15.21	11.23	8	36274	372	29537873
Reversible airways obstruction	15.18	11.23	7	36275	244	29538001
Toxic optic neuropathy	14.89	11.23	10	36272	731	29537514
Malignant neoplasm progression	14.86	11.23	44	36238	73815	29464430
Long QT syndrome	14.83	11.23	16	36266	2242	29536003
Ocular discomfort	14.82	11.23	14	36268	1675	29536570
Platelet count decreased	14.80	11.23	72	36210	104600	29433645
Drug intolerance	14.57	11.23	23	36259	48356	29489889
Diaphragmatic disorder	14.53	11.23	11	36271	971	29537274
Subcutaneous emphysema	14.44	11.23	11	36271	981	29537264
Sneezing	14.26	11.23	22	36260	4392	29533853
Exposure via skin contact	14.18	11.23	4	36278	31	29538214
Status asthmaticus	14.17	11.23	7	36275	285	29537960
Neutropenia	14.14	11.23	99	36183	131612	29406633
Respiratory rate increased	13.80	11.23	32	36250	8676	29529569
Suicide attempt	13.66	11.23	13	36269	34097	29504148
Back injury	13.62	11.23	19	36263	3465	29534780
Breath sounds abnormal	13.34	11.23	24	36258	5433	29532812
Psoriasis	13.24	11.23	12	36270	32215	29506030
Drug resistance	13.11	11.23	5	36277	21535	29516710
Vital capacity decreased	12.78	11.23	7	36275	353	29537892
Drug ineffective	12.71	11.23	344	35938	362826	29175419
Death	12.50	11.23	322	35960	341762	29196483
Occupational exposure to air contaminants	12.39	11.23	5	36277	125	29538120
Therapeutic product effect prolonged	12.36	11.23	6	36276	235	29538010
Foetal distress syndrome	12.22	11.23	10	36272	989	29537256
Tachycardia	12.10	11.23	139	36143	72271	29465974
Headache	12.07	11.23	146	36136	173861	29364384
Lung diffusion test decreased	11.98	11.23	8	36274	579	29537666
Seasonal allergy	11.92	11.23	22	36260	5080	29533165
Haemoptysis	11.86	11.23	71	36211	30479	29507766
Rhinovirus infection	11.78	11.23	17	36265	3199	29535046
Cytomegalovirus infection	11.66	11.23	7	36275	23208	29515037
Pancreatitis acute	11.37	11.23	8	36274	24377	29513868
Cyanosis	11.35	11.23	35	36247	11232	29527013
Blister rupture	11.27	11.23	5	36277	159	29538086

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	1448.93	10.47	1043	71132	94182	64332375
Wheezing	885.51	10.47	728	71447	79851	64346706
Chronic obstructive pulmonary disease	663.83	10.47	585	71590	70463	64356094
Obstructive airways disorder	656.08	10.47	376	71799	22809	64403748
Dyspnoea	524.48	10.47	1875	70300	716799	63709758
Full blood count abnormal	337.19	10.47	274	71901	29483	64397074
Productive cough	287.18	10.47	381	71794	72822	64353735
Cough	284.76	10.47	862	71313	301286	64125271
Pneumonia	267.26	10.47	1284	70891	558292	63868265
Completed suicide	215.96	10.47	8	72167	224406	64202151
Chest discomfort	205.66	10.47	422	71753	115684	64310873
Sputum discoloured	199.25	10.47	163	72012	17693	64408864
Asthma-chronic obstructive pulmonary disease overlap syndrome	196.61	10.47	66	72109	1059	64425498
Nasal congestion	152.41	10.47	254	71921	59404	64367153
Toxicity to various agents	150.93	10.47	112	72063	363401	64063156
Sleep disorder due to a general medical condition	147.72	10.47	100	72075	8134	64418423
Middle insomnia	142.51	10.47	117	72058	12760	64413797
Appendicolith	139.27	10.47	71	72104	3398	64423159
Forced expiratory volume decreased	129.43	10.47	86	72089	6781	64419776
Bronchiectasis	127.01	10.47	114	72061	14026	64412531
Respiratory failure	118.33	10.47	423	71752	160760	64265797
Pulmonary function test decreased	114.79	10.47	78	72097	6383	64420174
Dyspnoea exertional	110.96	10.47	251	71924	73479	64353078
Drug abuse	108.66	10.47	11	72164	132363	64294194
Nasal obstruction	105.59	10.47	44	72131	1315	64425242
Lower respiratory tract infection	105.31	10.47	287	71888	94327	64332230
Drug intolerance	104.17	10.47	40	72135	187952	64238605
Breath sounds abnormal	102.68	10.47	93	72082	11576	64414981
Therapeutic product effect incomplete	101.61	10.47	300	71875	103182	64323375
Oxygen saturation decreased	100.79	10.47	306	71869	106870	64319687
Bronchitis	94.43	10.47	302	71873	108441	64318116
Respiratory distress	91.13	10.47	189	71986	52142	64374415
Upper-airway cough syndrome	85.34	10.47	74	72101	8696	64417861
Synovitis	84.62	10.47	7	72168	99083	64327474
Bronchospasm	83.63	10.47	112	72063	21570	64404987
Hypercapnia	83.24	10.47	69	72106	7625	64418932
Nasal turbinate hypertrophy	82.09	10.47	29	72146	546	64426011
Eosinophilia	81.48	10.47	150	72025	37926	64388631
Bronchial neoplasm	73.52	10.47	25	72150	418	64426139
Respiratory disorder	73.20	10.47	139	72036	35972	64390585
Acute respiratory failure	70.71	10.47	166	72009	49768	64376789
Off label use	70.37	10.47	418	71757	632388	63794169
Drug ineffective	69.28	10.47	605	71570	839642	63586915
Alopecia	68.71	10.47	51	72124	165639	64260918
Treatment failure	67.84	10.47	23	72152	116793	64309764
Rheumatoid arthritis	67.57	10.47	51	72124	164243	64262314
Rhonchi	66.79	10.47	44	72131	3419	64423138
Tachypnoea	66.32	10.47	112	72063	26459	64400098
Ventricular failure	66.17	10.47	24	72151	489	64426068
Appendicitis	64.86	10.47	78	72097	13491	64413066
Hyper IgE syndrome	63.26	10.47	23	72152	472	64426085
Systemic lupus erythematosus	62.27	10.47	7	72168	77605	64348952
Infusion related reaction	61.53	10.47	56	72119	164411	64262146
Stress	60.83	10.47	177	71998	60357	64366200
Toxic epidermal necrolysis	59.80	10.47	130	72045	37036	64389521
Endometrial ablation	59.11	10.47	25	72150	776	64425781
Respiration abnormal	58.87	10.47	52	72123	6263	64420294
Sleep apnoea syndrome	58.21	10.47	113	72062	29719	64396838
Restrictive pulmonary disease	58.14	10.47	34	72141	2138	64424419
Blood immunoglobulin E increased	58.02	10.47	42	72133	3802	64422755
Hepatic enzyme increased	57.85	10.47	37	72138	129906	64296651
Emphysema	56.29	10.47	74	72101	13995	64412562
Rales	56.19	10.47	77	72098	15152	64411405
Lung hyperinflation	53.35	10.47	29	72146	1583	64424974
Blood test abnormal	53.22	10.47	69	72106	12874	64413683
Pain	53.16	10.47	382	71793	553129	63873428
Hypoxia	52.04	10.47	216	71959	87933	64338624
Contraindicated product administered	51.82	10.47	28	72147	107801	64318756
Arthropathy	51.75	10.47	36	72139	120931	64305626
Mycobacterium avium complex infection	50.44	10.47	39	72136	3901	64422656
Pemphigus	49.91	10.47	5	72170	60696	64365861
Haemoptysis	49.84	10.47	144	72031	48904	64377653
Bronchial haemorrhage	49.02	10.47	25	72150	1197	64425360
Pericarditis	46.87	10.47	7	72168	62509	64364048
Glossodynia	46.80	10.47	8	72167	64688	64361869
Joint swelling	46.44	10.47	108	72067	215274	64211283
Cardiogenic shock	46.12	10.47	108	72067	32319	64394238
Prolonged expiration	45.59	10.47	21	72154	802	64425755
Respiratory rate increased	45.39	10.47	77	72098	18254	64408303
Heart sounds	45.10	10.47	19	72156	584	64425973
Arthralgia	43.99	10.47	302	71873	441958	63984599
Febrile neutropenia	43.84	10.47	90	72085	187567	64238990
Bronchial disorder	43.55	10.47	28	72147	2087	64424470
Hypoventilation	43.54	10.47	43	72132	5963	64420594
Therapeutic product effect decreased	43.46	10.47	39	72136	115312	64311245
Sinus pain	43.03	10.47	30	72145	2559	64423998
Diarrhoea	42.60	10.47	562	71613	722142	63704415
Infective pulmonary exacerbation of cystic fibrosis	42.56	10.47	59	72116	11737	64414820
Status asthmaticus	42.34	10.47	21	72154	947	64425610
Rash	41.81	10.47	321	71854	458228	63968329
PCO2 increased	41.75	10.47	25	72150	1642	64424915
Oesophageal spasm	41.36	10.47	29	72146	2496	64424061
Lung consolidation	41.07	10.47	47	72128	7711	64418846
Intentional overdose	40.87	10.47	25	72150	89919	64336638
Respiratory acidosis	39.68	10.47	52	72123	9803	64416754
Rhinitis	39.07	10.47	54	72121	10711	64415846
Lung disorder	38.41	10.47	152	72023	60548	64366009
Respiratory tract infection	38.17	10.47	110	72065	37297	64389260
Pulmonary function test abnormal	37.65	10.47	30	72145	3134	64423423
Sight disability	37.42	10.47	11	72164	111	64426446
PO2 decreased	37.25	10.47	28	72147	2685	64423872
Upper respiratory tract infection	36.60	10.47	170	72005	72615	64353942
COVID-19 treatment	36.51	10.47	15	72160	432	64426125
Painful respiration	36.21	10.47	29	72146	3052	64423505
Cardiac murmur	36.10	10.47	54	72121	11509	64415048
Nasal polyps	36.08	10.47	31	72144	3598	64422959
Maternal exposure during pregnancy	35.42	10.47	33	72142	95851	64330706
Chest injury	35.40	10.47	26	72149	2407	64424150
Breast conserving surgery	35.28	10.47	16	72159	589	64425968
Cyanosis	33.95	10.47	76	72099	22079	64404478
Thermohypoaesthesia	33.92	10.47	10	72165	102	64426455
Vocal cord dysfunction	33.83	10.47	14	72161	411	64426146
Polycystic ovaries	33.56	10.47	24	72151	2131	64424426
Loss of personal independence in daily activities	33.37	10.47	165	72010	72289	64354268
Sinus tachycardia	33.18	10.47	95	72080	32093	64394464
Total lung capacity increased	32.88	10.47	16	72159	692	64425865
Overdose	32.81	10.47	82	72093	159484	64267073
Gastrooesophageal reflux disease	32.55	10.47	181	71994	82962	64343595
Influenza B virus test positive	32.53	10.47	13	72162	348	64426209
Influenza	31.66	10.47	216	71959	106315	64320242
Oesophageal pain	30.68	10.47	27	72148	3236	64423321
Airway peak pressure increased	29.90	10.47	12	72163	325	64426232
Kyphosis	29.14	10.47	23	72152	2370	64424187
Pulmonary hypertension	28.90	10.47	110	72065	43029	64383528
Sneezing	28.82	10.47	57	72118	15194	64411363
Peak expiratory flow rate decreased	28.59	10.47	14	72161	614	64425943
Rib deformity	28.41	10.47	9	72166	119	64426438
Exposure during pregnancy	28.38	10.47	27	72148	77648	64348909
Reversible airways obstruction	28.33	10.47	17	72158	1121	64425436
Throat clearing	28.26	10.47	18	72157	1320	64425237
Pneumonitis	27.84	10.47	121	72054	50244	64376313
Heart rate increased	27.52	10.47	197	71978	98478	64328079
Frustration tolerance decreased	27.31	10.47	34	72141	6091	64420466
Neuropathy peripheral	26.90	10.47	57	72118	117468	64309089
Venous pressure jugular increased	26.70	10.47	17	72158	1246	64425311
Blister	26.38	10.47	31	72144	80936	64345621
Atrial fibrillation	26.28	10.47	300	71875	170789	64255768
Abdominal discomfort	26.13	10.47	110	72065	182212	64244345
Asthmatic crisis	26.08	10.47	19	72156	1737	64424820
Sinus disorder	25.90	10.47	58	72117	16850	64409707
Hyperkaliuria	25.65	10.47	9	72166	166	64426391
Type 2 diabetes mellitus	25.53	10.47	90	72085	33930	64392627
Wolff-Parkinson-White syndrome	25.52	10.47	10	72165	254	64426303
Injection site erythema	25.41	10.47	25	72150	70775	64355782
Chronic respiratory failure	25.38	10.47	22	72153	2584	64423973
Product use issue	25.33	10.47	86	72089	151629	64274928
Swelling	25.29	10.47	93	72082	160125	64266432
Injection site bruising	25.23	10.47	5	72170	36368	64390189
Helicobacter infection	25.13	10.47	6	72169	38356	64388201
Bronchopulmonary aspergillosis allergic	25.11	10.47	18	72157	1604	64424953
Seasonal allergy	24.83	10.47	46	72129	11680	64414877
Injection site pain	24.69	10.47	55	72120	111353	64315204
Separation anxiety disorder	24.40	10.47	6	72169	28	64426529
Cardiac failure congestive	24.29	10.47	238	71937	130342	64296215
Wound	24.15	10.47	30	72145	76447	64350110
Total lung capacity decreased	24.15	10.47	18	72157	1704	64424853
Genital herpes simplex	23.93	10.47	10	72165	301	64426256
Lactose intolerance	23.75	10.47	19	72156	1997	64424560
Eye pruritus	23.54	10.47	47	72128	12612	64413945
Duodenal ulcer perforation	23.52	10.47	5	72170	34620	64391937
Drug-induced liver injury	23.43	10.47	12	72163	47631	64378926
Respiratory gas exchange disorder	23.22	10.47	13	72162	752	64425805
Respiratory tract congestion	23.16	10.47	54	72121	16111	64410446
Aortic aneurysm	23.12	10.47	35	72140	7539	64419018
Multiple organ dysfunction syndrome	22.49	10.47	192	71983	101221	64325336
Red blood cell sedimentation rate increased	22.29	10.47	4	72171	31231	64395326
Sputum purulent	22.25	10.47	15	72160	1211	64425346
Nausea	22.03	10.47	691	71484	785109	63641448
Drug resistance	22.01	10.47	6	72169	35096	64391461
Sensitivity to weather change	21.89	10.47	32	72143	6682	64419875
Dysphonia	21.62	10.47	106	72069	46276	64380281
Ventricular fibrillation	21.35	10.47	67	72108	23793	64402764
Pulmonary mass	21.09	10.47	67	72108	23949	64402608
Affective disorder	20.93	10.47	31	72144	6549	64420008
Multiple sclerosis relapse	20.77	10.47	10	72165	41125	64385432
Psoriasis	20.74	10.47	30	72145	71673	64354884
Granuloma	20.71	10.47	31	72144	6610	64419947
Oral candidiasis	20.61	10.47	65	72110	23147	64403410
Drug hypersensitivity	20.45	10.47	169	72006	237646	64188911
Osteopenia	20.21	10.47	50	72125	15490	64411067
FEV1/FVC ratio decreased	20.05	10.47	7	72168	127	64426430
Throat irritation	19.96	10.47	81	72094	32630	64393927
Laryngeal stenosis	19.95	10.47	12	72163	795	64425762
Multimorbidity	19.86	10.47	13	72162	999	64425558
White blood cell count decreased	19.78	10.47	100	72075	157737	64268820
Rectal prolapse	19.76	10.47	16	72159	1710	64424847
Humidity intolerance	19.73	10.47	9	72166	336	64426221
Bundle branch block left	19.56	10.47	38	72137	9996	64416561
Pneumonia viral	19.55	10.47	33	72142	7789	64418768
Cor pulmonale	19.53	10.47	17	72158	2008	64424549
Colitis ischaemic	19.42	10.47	45	72130	13369	64413188
Forced vital capacity decreased	19.39	10.47	15	72160	1501	64425056
Bronchospasm paradoxical	19.33	10.47	7	72168	142	64426415
Dyslipidaemia	19.25	10.47	36	72139	9206	64417351
Long QT syndrome	18.98	10.47	26	72149	5113	64421444
Peak expiratory flow rate abnormal	18.96	10.47	6	72169	79	64426478
Platelet count decreased	18.95	10.47	110	72065	167601	64258956
Chest pain	18.95	10.47	370	71805	235610	64190947
Fatigue	18.94	10.47	667	71508	748063	63678494
Blood pH decreased	18.93	10.47	24	72151	4378	64422179
Total lung capacity abnormal	18.72	10.47	7	72168	156	64426401
Subcutaneous emphysema	18.60	10.47	15	72160	1594	64424963
Injection site reaction	18.52	10.47	15	72160	46649	64379908
Bronchial hyperreactivity	18.24	10.47	18	72157	2494	64424063
Injection site swelling	18.09	10.47	12	72163	41341	64385216
Lung opacity	17.99	10.47	20	72155	3179	64423378
Diaphragmatic disorder	17.98	10.47	14	72161	1414	64425143
Palmar-plantar erythrodysaesthesia syndrome	17.93	10.47	5	72170	28814	64397743
Liver disorder	17.84	10.47	20	72155	53331	64373226
Carbon dioxide increased	17.79	10.47	16	72159	1973	64424584
Bilirubin conjugated abnormal	17.77	10.47	6	72169	98	64426459
Tachycardia	17.73	10.47	250	71925	149329	64277228
Malaise	17.70	10.47	574	71601	395673	64030884
Muscle injury	17.58	10.47	4	72171	26433	64400124
Suicide attempt	17.48	10.47	33	72142	70974	64355583
Cytomegalovirus infection	17.37	10.47	10	72165	37189	64389368
Pneumonia staphylococcal	17.35	10.47	23	72152	4383	64422174
Psoriatic arthropathy	17.07	10.47	14	72161	43267	64383290
Dust allergy	17.03	10.47	12	72163	1041	64425516
Brain hypoxia	16.92	10.47	11	72164	836	64425721
Eosinophil count increased	16.89	10.47	44	72131	14068	64412489
Neutropenia	16.86	10.47	179	71996	239445	64187112
Impaired healing	16.81	10.47	26	72149	60447	64366110
Hepatic function abnormal	16.62	10.47	29	72146	64284	64362273
Dystrophic calcification	16.55	10.47	6	72169	122	64426435
Injection site pruritus	16.51	10.47	11	72164	37815	64388742
Headache	16.44	10.47	459	71716	529008	63897549
Bronchial wall thickening	16.39	10.47	15	72160	1892	64424665
Basal cell carcinoma	16.35	10.47	7	72168	30831	64395726
Oedema peripheral	16.29	10.47	328	71847	209989	64216568
Hypohidrosis	16.26	10.47	7	72168	227	64426330
Rhinitis allergic	16.25	10.47	31	72144	8047	64418510
Irritable bowel syndrome	16.13	10.47	11	72164	37358	64389199
Intentional product use issue	15.95	10.47	54	72121	95310	64331247
Toxic optic neuropathy	15.80	10.47	11	72164	936	64425621
Rhinorrhoea	15.72	10.47	118	72057	59851	64366706
Pneumonia pseudomonal	15.45	10.47	23	72152	4880	64421677
Sopor	15.30	10.47	7	72168	29654	64396903
Hyponatraemia	15.27	10.47	242	71933	148097	64278460
Pupillary reflex impaired	15.24	10.47	18	72157	3055	64423502
Lymphoedema	15.20	10.47	34	72141	9871	64416686
Eosinophil count abnormal	15.14	10.47	9	72166	583	64425974
Pneumocystis jirovecii pneumonia	15.09	10.47	6	72169	27628	64398929
Drug ineffective for unapproved indication	15.07	10.47	8	72167	31125	64395432
C-reactive protein increased	15.03	10.47	55	72120	94854	64331703
Malignant neoplasm progression	15.01	10.47	70	72105	112801	64313756
Gastrointestinal disorder	14.87	10.47	51	72124	89658	64336899
Aspiration	14.73	10.47	47	72128	16838	64409719
Hip arthroplasty	14.67	10.47	3	72172	21348	64405209
Suicidal ideation	14.62	10.47	33	72142	66509	64360048
Lung neoplasm malignant	14.62	10.47	55	72120	21393	64405164
General physical health deterioration	14.58	10.47	315	71860	204110	64222447
Lactic acidosis	14.53	10.47	118	72057	61292	64365265
Abortion spontaneous	14.50	10.47	5	72170	25138	64401419
Neuromyelitis optica spectrum disorder	14.40	10.47	10	72165	847	64425710
Generalised tonic-clonic seizure	14.39	10.47	14	72161	39843	64386714
Discomfort	14.08	10.47	45	72130	80833	64345724
Type IIa hyperlipidaemia	14.07	10.47	6	72169	190	64426367
Heparin-induced thrombocytopenia	14.03	10.47	30	72145	8449	64418108
Bone marrow failure	13.93	10.47	20	72155	47932	64378625
Pneumothorax	13.90	10.47	59	72116	24239	64402318
Pneumonia respiratory syncytial viral	13.77	10.47	12	72163	1419	64425138
Walking aid user	13.75	10.47	25	72150	6256	64420301
Vascular parkinsonism	13.73	10.47	5	72170	103	64426454
Pancytopenia	13.64	10.47	99	72076	143210	64283347
Pneumonia haemophilus	13.57	10.47	10	72165	930	64425627
Disease progression	13.42	10.47	98	72077	141582	64284975
Stomatitis	13.41	10.47	70	72105	109535	64317022
Respiratory alkalosis	13.33	10.47	19	72156	3878	64422679
Product prescribing error	13.28	10.47	76	72099	35193	64391364
Catarrh	13.13	10.47	8	72167	542	64426015
Tracheomalacia	13.10	10.47	6	72169	226	64426331
Secretion discharge	13.00	10.47	36	72139	11928	64414629
Extrapyramidal disorder	12.92	10.47	3	72172	19549	64407008
Hyperlactacidaemia	12.86	10.47	21	72154	4823	64421734
Occupational exposure to air contaminants	12.83	10.47	5	72170	125	64426432
Tracheitis	12.78	10.47	11	72164	1279	64425278
Amaurosis	12.64	10.47	10	72165	1034	64425523
Depressive symptom	12.64	10.47	20	72155	4476	64422081
Tracheal disorder	12.52	10.47	7	72168	404	64426153
Supraventricular tachycardia	12.49	10.47	48	72127	18859	64407698
Nephrocalcinosis	12.46	10.47	11	72164	1323	64425234
Glycosylated haemoglobin decreased	12.30	10.47	8	72167	608	64425949
Musculoskeletal stiffness	12.27	10.47	84	72091	123122	64303435
Haematoma	12.12	10.47	91	72084	46159	64380398
Myelodysplastic syndrome	12.06	10.47	8	72167	27571	64398986
Pharyngeal mass	12.05	10.47	6	72169	273	64426284
Loss of consciousness	12.04	10.47	107	72068	148258	64278299
Cardiac disorder	12.01	10.47	105	72070	55711	64370846
C-reactive protein abnormal	11.95	10.47	9	72166	29038	64397519
Dry eye	11.93	10.47	9	72166	29010	64397547
Tumour hyperprogression	11.92	10.47	5	72170	152	64426405
Hypochloraemia	11.79	10.47	13	72162	2048	64424509
Oral herpes	11.79	10.47	5	72170	22147	64404410
Arthritis	11.73	10.47	51	72124	83763	64342794
Oesophageal motility disorder	11.63	10.47	7	72168	464	64426093
Infective exacerbation of chronic obstructive airways disease	11.63	10.47	14	72161	2424	64424133
Product use in unapproved indication	11.59	10.47	134	72041	176484	64250073
Knee arthroplasty	11.59	10.47	8	72167	26991	64399566
Visceral pain	11.57	10.47	3	72172	18	64426539
Neutrophil count decreased	11.41	10.47	46	72129	77150	64349407
Abdominal distension	11.19	10.47	160	72015	95834	64330723
Blood pressure fluctuation	11.17	10.47	26	72149	51845	64374712
Myocardial infarction	11.03	10.47	253	71922	165568	64260989
Hypertrophic cardiomyopathy	10.97	10.47	12	72163	1874	64424683
Idiopathic intracranial hypertension	10.94	10.47	14	72161	2579	64423978
Appetite disorder	10.85	10.47	23	72152	6438	64420119
Idiopathic pulmonary fibrosis	10.81	10.47	17	72158	3783	64422774
Mucosal inflammation	10.77	10.47	35	72140	62549	64364008
Intentional self-injury	10.72	10.47	10	72165	29034	64397523
Oropharyngeal pain	10.71	10.47	149	72026	88718	64337839
Acute myeloid leukaemia	10.68	10.47	9	72166	27454	64399103
Angle closure glaucoma	10.67	10.47	14	72161	2643	64423914
Bronchitis viral	10.57	10.47	9	72166	1031	64425526
Drug eruption	10.57	10.47	15	72160	36121	64390436
Decreased appetite	10.56	10.47	237	71938	281052	64145505
Blood immunoglobulin E abnormal	10.51	10.47	3	72172	27	64426530
Pancreatitis	10.49	10.47	33	72142	59574	64366983

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R01AX03	RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Other nasal preparations
ATC	R03AL01	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC	R03AL02	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC	R03BB01	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS Anticholinergics
FDA MoA	N0000175370	Cholinergic Antagonists
FDA EPC	N0000175574	Anticholinergic
MeSH PA	D018927	Anti-Asthmatic Agents
MeSH PA	D001993	Bronchodilator Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D019141	Respiratory System Agents
CHEBI has role	CHEBI:35523	bronchodilator
CHEBI has role	CHEBI:48876	muscarinic antagonists
CHEBI has role	CHEBI:53784	antispasmodics

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Bronchospasm	indication	4386001
Chronic obstructive lung disease	indication	13645005	DOID:3083
Bronchitis	indication	32398004	DOID:6132
Allergic rhinitis	indication	61582004
Nasal discharge	indication	64531003
Pulmonary emphysema	indication	87433001
Chronic Obstructive Pulmonary Disease with Bronchospasms	indication
Asthma	off-label use	195967001	DOID:2841
Asthma-chronic obstructive pulmonary disease overlap syndrome	off-label use	10692761000119107
Ocular hypertension	contraindication	4210003	DOID:9282
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Hypokalemia	contraindication	43339004
Conduction disorder of the heart	contraindication	44808001
Ketoacidosis	contraindication	56051008
Metabolic acidosis	contraindication	59455009
Diabetes mellitus	contraindication	73211009	DOID:9351
Paradoxical bronchospasm	contraindication	102578005
Prolonged QT interval	contraindication	111975006
Seizure disorder	contraindication	128613002
Bladder outflow obstruction	contraindication	236645006
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Chronic myocardial ischemia	contraindication	413844008	DOID:3393
Myocardial ischemia	contraindication	414795007	DOID:3393
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.24	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Ki	9.29		WOMBAT-PK	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	8.82		WOMBAT-PK
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	9.18		WOMBAT-PK
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	8.77		WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	9.31		WOMBAT-PK
Solute carrier family 22 member 2	Transporter	O15244	S22A2_HUMAN		IC50	4.82		WOMBAT-PK
Muscarinic acetylcholine receptor M2	GPCR		ACM2_RAT		Ki	9.11		CHEMBL
Muscarinic acetylcholine receptor M1	GPCR		ACM1_RAT		Ki	9.54		CHEMBL
Muscarinic acetylcholine receptor M3	GPCR		ACM3_RAT		Ki	9.74		CHEMBL

External reference:

ID	Source
4019791	VUID
N0000147880	NUI
D02212	KEGG_DRUG
66985-17-9	SECONDARY_CAS_RN
4019341	VANDF
4019791	VANDF
C0027235	UMLSCUI
CHEBI:5956	CHEBI
X8M	PDB_CHEM_ID
CHEMBL1621597	ChEMBL_ID
DB00332	DRUGBANK_ID
CHEMBL1464005	ChEMBL_ID
CHEMBL2134724	ChEMBL_ID
D009241	MESH_DESCRIPTOR_UI
6604365	PUBCHEM_CID
325	IUPHAR_LIGAND_ID
GR88G0I6UL	UNII
1309404	RXNORM
4916	MMSL
6256	MMSL
d00265	MMSL
001750	NDDF
004943	NDDF
108624006	SNOMEDCT_US
372518007	SNOMEDCT_US
386881005	SNOMEDCT_US
725862005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ipratropium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0045	SPRAY	21 ug	NASAL	ANDA	3 sections
Ipratropium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0046	SPRAY	42 ug	NASAL	ANDA	16 sections
Ipratropium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	0378-7970	SOLUTION	0.50 mg	RESPIRATORY (INHALATION)	ANDA	22 sections
Ipratropium Bromide and Albuterol Sulfate	HUMAN PRESCRIPTION DRUG LABEL	2	0378-9671	SOLUTION	0.50 mg	RESPIRATORY (INHALATION)	ANDA	28 sections
Ipratropium Bromide and Albuterol Sulfate	HUMAN PRESCRIPTION DRUG LABEL	2	0487-0201	SOLUTION	0.50 mg	RESPIRATORY (INHALATION)	ANDA	28 sections
Ipratropium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	0487-9801	SOLUTION	0.50 mg	RESPIRATORY (INHALATION)	ANDA	22 sections
Ipratropium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3798	SOLUTION	0.50 mg	RESPIRATORY (INHALATION)	ANDA	20 sections
Combivent Respimat	HUMAN PRESCRIPTION DRUG LABEL	2	0597-0024	SPRAY, METERED	20 ug	RESPIRATORY (INHALATION)	NDA	27 sections
Atrovent HFA	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0087	AEROSOL, METERED	17 ug	RESPIRATORY (INHALATION)	NDA	29 sections
Ipratropium Bromide and Albuterol Sulfate	HUMAN PRESCRIPTION DRUG LABEL	2	0781-7146	SOLUTION	0.50 mg	RESPIRATORY (INHALATION)	ANDA	28 sections
Ipratropium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	0781-7157	SOLUTION	0.50 mg	RESPIRATORY (INHALATION)	ANDA	23 sections
Ipratropium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	16714-526	SPRAY, METERED	21 ug	NASAL	ANDA	24 sections
Ipratropium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	16714-527	SPRAY, METERED	42 ug	NASAL	ANDA	25 sections
Ipratropium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	21695-911	SOLUTION	0.50 mg	RESPIRATORY (INHALATION)	ANDA	21 sections
Ipratropium bromide	HUMAN PRESCRIPTION DRUG LABEL	1	24208-398	SPRAY, METERED	21 ug	NASAL	ANDA	27 sections
Ipratropium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	24208-399	SPRAY, METERED	42 ug	NASAL	ANDA	25 sections
Ipratropium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	42254-041	SOLUTION	0.50 mg	RESPIRATORY (INHALATION)	ANDA	19 sections
Ipratropium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	42254-355	SPRAY, METERED	42 ug	NASAL	ANDA	25 sections
Ipratropium Bromide	Human Prescription Drug Label	1	47335-706	SOLUTION	0.50 mg	RESPIRATORY (INHALATION)	ANDA	19 sections
Ipratropium Bromide	Human Prescription Drug Label	1	47335-706	SOLUTION	0.50 mg	RESPIRATORY (INHALATION)	ANDA	19 sections
Ipratropium Bromide and Albuterol Sulfate	Human Prescription Drug Label	2	47335-756	SOLUTION	0.50 mg	RESPIRATORY (INHALATION)	ANDA	22 sections
Ipratropium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0668	SOLUTION	0.50 mg	RESPIRATORY (INHALATION)	ANDA	21 sections
AtroventHFA	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0961	AEROSOL, METERED	17 ug	RESPIRATORY (INHALATION)	NDA	25 sections
IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE	HUMAN PRESCRIPTION DRUG LABEL	2	50090-1382	SOLUTION	0.50 mg	RESPIRATORY (INHALATION)	ANDA	26 sections
Ipratropium Bromide and Albuterol Sulfate	HUMAN PRESCRIPTION DRUG LABEL	2	50090-1669	SOLUTION	0.50 mg	RESPIRATORY (INHALATION)	ANDA	27 sections
Ipratropium Bromide and Albuterol Sulfate	HUMAN PRESCRIPTION DRUG LABEL	2	50090-2567	SOLUTION	0.50 mg	RESPIRATORY (INHALATION)	ANDA	27 sections
IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE	HUMAN PRESCRIPTION DRUG LABEL	2	50090-4103	SOLUTION	0.50 mg	RESPIRATORY (INHALATION)	ANDA	26 sections
Ipratropium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4185	SOLUTION	0.50 mg	RESPIRATORY (INHALATION)	ANDA	22 sections
Ipratropium Bromide	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5968	SPRAY, METERED	42 ug	NASAL	ANDA	24 sections
AtroventHFA	HUMAN PRESCRIPTION DRUG LABEL	1	53002-8410	AEROSOL, METERED	17 ug	RESPIRATORY (INHALATION)	NDA	28 sections